Stage IB Hepatocellular Carcinoma AJCC v8
Oncology·MeSH: Carcinoma, Hepatocellular
Prevalence
12.0 / 100K
Incidence
8.6 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Regorafenib | UNITED THERAPEUTICS Corp (UTHR) |
Frequently asked questions
How many drugs are in development for Stage IB Hepatocellular Carcinoma AJCC v8?
BioSniper tracks 1 drug in development for Stage IB Hepatocellular Carcinoma AJCC v8 across 1 company.
How many clinical trials target Stage IB Hepatocellular Carcinoma AJCC v8?
There are 1 clinical trial targeting Stage IB Hepatocellular Carcinoma AJCC v8 tracked by BioSniper.
What is the prevalence of Stage IB Hepatocellular Carcinoma AJCC v8?
The estimated prevalence of Stage IB Hepatocellular Carcinoma AJCC v8 is approximately 12.0 per 100,000 population.
Deep-dive into Stage IB Hepatocellular Carcinoma AJCC v8
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis